NABI, a NASDAQ-listed company headquartered in Boca Raton, FL, is the world's
largest independent provider of human plasma elements to the health care industry. TheCompany collects, processes, tests and distributes plasma and plasma-based products for thediagnosis, treatment and therapy of immune disorders. NABI's plasma collection operations encompass 78 locations, with 76 centers in 30 U.S. states and 2 in Germany. NABI also markets and sells H©BIG, a proprietary immune globulin therapeutic product which provides passive immunity to hepatitis B, and is concluding Phase III human clinical trials of HIV©IG, another immunoglobulin intended to prevent HIV transmission from infected mothers to their unborn children.

Univax Biologics, Inc. develops and markets products for the prevention and treatment of autoimmune and serious infectious diseases and their associated complications through activation and targeting of the human immune system. Univax currently markets one product, WinRho SD, a product designed for the treatment of immune thrombocytopenic purpura (ITP) and the suppression of Rh isoimmunization. Univax has several other products in various stages of clinical trials, and has collaborative agreements with such biotechnology companies as Genzyme Corporation and Chiron Corporation for the development of additional immune globulin therapeutic products.

The stock for stock merger created a first-tier biopharmaceutical company with revenues of approximately $200 million. The new company, which will temporarily retain the NABI name, was formed through the issuance of .79 shares of NABI stock to Univax shareholders in exchange for each Univax share held. The merged company, which will be fully integrated, combines NABI's large scale plasma collection, manufacturing and financial resources with Univax's plasma donor stimulation technology, vaccine and immunoglobulin pipeline and sales and marketing presences.

BNY Associates Incorporated, a subsidiary of the Bank of New York, was retained to assist NABI's management in evaluating the strategic and financial merits of the prospective transaction. BNYA also advised NABI in the negotiation of the common stock exchange ratio and the transaction structure and assisted NABI's management in their review of the operations and financial condition of Univax. The investment bankers of BNY Associates that provided the above services are now employed by Stonebridge Associates, LLC, an investment banking firm formed by the Boston employees of BNY Associates.